Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

WOUNDCOM

Financiado

Cerrado

The first bioactive wound dressing exploiting the unique wound healing and ant...

The first bioactive wound dressing exploiting the unique wound healing and antimicrobial properties of human collagen VI Chronic wounds are a global problem. They severely impair the quality of life for 200 million patients worldwide and generate vast medical costs. It is a problem that will only escalate with the increasing incidence of conditions... ver más

31/12/2025

COLZYX AB

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

COLZYX AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-04-24

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

COLZYX AB

2.51M€ | Lider

MADERAS MEJORADAS INDUSTRIAL

529.09K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

WOUNDCOM Interactive biomembranes for wound management exploiting t... 71K€ Cerrado

BIOCURE Novel Biomaterial for Improved and Cost efficient Wound Heal... 2M€ Cerrado

NATURALSKIN Rapid absorption denaturalized collagen dressings 71K€ Cerrado

IPT-2012-0602-300000 FIBRODRESS: Desarrollo de un apósito bioactivo basado en fib... 2K€ Cerrado

MULTIZONAL SCAFFOLD Multizonal scaffold system based on collagen and copper dope... 171K€ Cerrado

MAT2012-32668 APOSITOS ACTIVOS PARA HERIDAS CRONICAS BASADOS EN BIOPOLIMER... 53K€ Cerrado

Duración del proyecto: 68 meses Fecha Inicio: 2020-04-24
Fecha Fin: 2025-12-31

Líder del proyecto

COLZYX AB No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Chronic wounds are a global problem. They severely impair the quality of life for 200 million patients worldwide and generate vast medical costs. It is a problem that will only escalate with the increasing incidence of conditions that impede wound healing, such as diabetes, obesity and vascular disorders. The available wound care options can manipulate one or multiple aspects of the wound environment but cannot form antibacterial barriers and facilitate healing to a satisfactory level at the same time. Effective wound care products to address both: rapid wound closure and combat of infection are, therefore, urgently needed. Colzyx aims to address the unmet challenges in wound management with its novel wound dressing. Basing on a ground-breaking discovery of wound healing and antimicrobial properties of human collagen VI and parts thereof, Colzyx has developed a product that has the potential to revolutionise wound management and create a new category of bioactive wound dressings. WOUNDCOM uses highly functional molecules that promote wound healing by mimicking natural body mechanisms and at the same time combat bacterial infection. This approach offers significant benefits to patients through reduction of pain and discomfort and accelerated recovery. It will also shorten hospitalisation time and decrease the associated financial burden. This project’s objective is to validate the efficacy and safety of WOUNDCOM and bring it to commercial readiness. The project builds on our SMEi Phase 1 project, which provided a valuable understanding of the current trends and opportunities on the wound management market, targeted users, competitors and potential partnerships. The feasibility study was used to optimise the business plan and prepare a synopsis for the clinical study. Successful evaluation of WOUNDCOM’s in the clinic will enable CE marking and support building the awareness and continued strategic partnerships for product manufacturing, marketing, and distribution.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores